skip to Main Content

Welcome to the press programme of The International Liver CongressTM 2017. Here you will find all media materials relating to abstracts selected for official press activities.

Background information can be accessed below:

The official press releases will be available in the table below on the day of scientific presentation and the press conference webcasts will be available 24 hours after each session.

Should you have any questions, please contact the Press Office at 

Press Release – Wednesday 19 April

Press Conference: Thursday 20 April, 08:00 – 09:00, D203/D204

To view the official ILC 2017 Press Conference webcast, please click here.

08:00Welcome and introductionsProfessor Laurent Castera, Hôpital Beaujon, France and EASL Secretary General
08:05Combined press release:

PS031: Tumor recurrence after interferon-free treatment for hepatitis C in patients with previously treated hepatocellular carcinoma discloses a more aggressive pattern and faster tumor growth

PS033: Hepatitis C virus-induced epigenetic and transcriptional changes persist post cure

PS034: Identifying residual risk of HCC following HCV eradication in compensated cirrhosis: Decision-tree and random forest models developed in the French multicenter prospective ANS CO12 CIRVIR cohort

PS035: Among cirrhotic patients with a hepatitis C sustained viral response, the risk of de-novo hepatocellular carcinoma relates to baseline factors and not the use of direct acting antivirals: Results from a nationwide cohort

PS036: Sustained virologic response by ledipasvir/sofosbuvir reduces the incidence of hepatocellular carcinoma in Japanese patients with HCV genotype 1 infection – Comparison with simeprevir with peginterferon plus ribavirin

PS037: No increase in the occurrence rate of hepatocellular carcinoma in Chinese treated by direct-acting antivirals compared to interferon after eradication of hepatitis C virus: A long-term follow-up

PS038: Occurrence of  hepatocellular carcinoma (HCC) in patients with HCV related liver disease  treated with direct-acting antivirals (DAAS)

Professor Massimo Colombo, Humanitas Research Hospital, Rozzano, Italy


08:25PS160: No evidence for higher risk of hepatocellular carcinoma occurrence or recurrence following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression


Dr Gregory Dore, The Kirby Institute, UNSW Sydney, Australia
08:35GS001: A randomized trial of 6-month Norfloxacin therapy in patients with Child-Pugh class C cirrhosisDr Richard Moreau, INSERM and Paris Diderot University, Paris, France
08:45Question and Answer sessionAll

Press Releases – Thursday 20 April


Press Conference: Friday 21 April, 11:30 – 12:30, D203/D204

To view the official ILC 2017 Press Conference webcast, please click here.

11:30Welcome and introductionsProfessor Tom Hemming Karlsen, Oslo University Hospital Rikshospitalet, Norway and EASL Vice-Secretary
11:35Launch of the WHO Global Hepatitis Report 2017Dr Gottfried Hirnschall, Director of Department of HIV and Global Hepatitis Programme
11:45GS007: ENDURANCE-3: Safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosisDr Graham Foster, Queen Mary University of London, United Kingdom
11:55GS010: Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: Checkmate 040 studyDr Bruno Sangro, Clinica Universidad de Navarra and Biomedical Research Network in Hepatic and Digestive Diseases (CIBEREHD),  Spain
12:05PS085: Fecal microbiota transplant using a precision medicine approach is safe, associated with lower hospitalization risk and improved cognitive function in recurrent hepatic encephalopathyDr Jasmohan S Bajaj, Virginia Commonwealth University, United States
12:15PS101: Ledipasvir/sofosbuvir ± ribavirin for 12 or 24 weeks is safe and effective in children 6-11 years old with chronic hepatitis C infectionDr Karen Murray, Seattle Children’s Hospital/University of Washington School of Medicine, United States
12:25Question and Answer sessionAll

Press Releases – Friday 21 April


Press Conference: Saturday 22 April, 12:30 – 13:30, D203/D204

To view the official ILC 2017 Press Conference webcast, please click here.

12:30Welcome and introductionsProfessor Frank Tacke, University Hospital Aachen, Germany and EASL Scientific Committee member
12:40LBO01: A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (BEZURSO)Dr Christophe Corpechot, Reference Center For Inflammatory Biliary Diseases, Saint-Antoine Hospital, France
12:50/CORRECTION: SARAH trial failed in meeting its primary endpoint/
GS012: SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma
Professor Valerie Vilgrain, Assistance Publique Hopitaux De Paris – Hopital Beaujon, France
13:00LBO08: Long-term albumin administration improves survival in patients with decompensated cirrhosis: Final results of the “ANSWER” studyProfessor Mauro Bernardi, Policlinico S. Orsola-Malpighi / University of Bologna, Italy
13:10LBP505: Restrictions for reimbursement of interferon-free direct-acting antiviral therapies for HCV infection in EuropeAlison Marshall, The Kirby Institute, UNSW Sydney, Australia
13:20Question and Answer SessionAll

Press Releases – Saturday 22 April